Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on INSM stock, giving a Buy rating on August 22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stephen Willey has given his Buy rating due to a combination of factors that highlight the potential of Insmed’s TPIP in the treatment of idiopathic pulmonary fibrosis (IPF). The recent positive results from the TETON-2 trial, which demonstrated significant improvements in lung function and quality of life for patients using Tyvaso, provide a strong foundation for the potential success of TPIP.
Willey notes that TPIP, a treprostinil prodrug with a more convenient dosing schedule, has shown superior clinical outcomes compared to Tyvaso in previous studies. This positions TPIP as a promising candidate for further development in IPF, especially given the established benefits of treprostinil in related conditions. The market’s positive reaction to the TETON-2 results, along with the potential for TPIP to capture a significant share in a lucrative market, supports Willey’s optimistic outlook for Insmed’s stock.
In another report released on August 22, Evercore ISI also initiated coverage with a Buy rating on the stock with a $110.00 price target.
Based on the recent corporate insider activity of 147 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year.